Physician profile
Stuart C Jennings
NPI 1851566434
$39,657.54
in general payments reported to CMS, 2019-2025
36 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $2,053 · 2021: $567 · 2022: $2,311 · 2023: $2,979 · 2024: $4,278 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Honoraria: $9,263 · Food and Beverage: $5,144 · Travel and Lodging: $4,796 · Consulting Fee: $3,038 · Education: $89.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,079.00 |
| Honoraria | $9,262.50 |
| Food and Beverage | $5,143.92 |
| Travel and Lodging | $4,795.88 |
| Consulting Fee | $3,037.50 |
| Education | $89.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,671.60 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Calliditas Therapeutics US INC. | $13,212.74 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $3,800.91 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $2,224.36 | 2022-2025 | Filspari |
| Nxstage Medical, INC. | $797.20 | 2022-2025 | Nxstage System One |
| Novartis Pharmaceuticals Corporation | $646.64 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $485.89 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $448.90 | 2021-2025 | Farxiga, Brilinta, Lokelma |
| Fresenius USA Marketing, INC. | $392.81 | 2019-2025 | Nxstage System One, Velphoro, Velphoro |
| Ge Healthcare | $347.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $324.61 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $312.34 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $272.08 | 2019-2024 | Veltassa |
| Glaxosmithkline, LLC. | $162.71 | 2021-2025 | Benlysta, Jesduvroq |
| Analog Devices INC. | $140.00 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $134.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.40 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $123.45 | 2022-2025 | Wegovy, Rivfloza, Ozempic |
| Daiichi Sankyo INC. | $110.49 | 2019-2023 | Injectafer |
| Mallinckrodt Hospital Products INC. | $104.52 | 2021-2025 | Acthar |
| Radiometer America, INC | $98.00 | 2025 | |
| Shield Therapeutics INC | $93.56 | 2024 | |
| Kyowa Kirin, INC. | $86.03 | 2024-2025 | Crysvita |
| Akebia Therapeutics INC | $83.46 | 2019-2022 | |
| Zoll Medical Corporation | $77.50 | 2023 | |
| Ardelyx, INC. | $59.64 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $56.38 | 2021-2023 | Ultomiris |
| Lilly USA, LLC | $55.51 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $48.80 | 2021-2023 | Oxlumo, Givlaari |
| Becton, Dickinson and Company | $39.00 | 2023 | |
| Pharmacosmos Therapeutics INC. | $30.88 | 2025 | Monoferric |
| Genzyme Corporation | $30.55 | 2022-2024 | |
| Scpharmaceuticals INC. | $18.62 | 2024 | |
| Chiesi USA, INC. | $17.06 | 2019 | |
| Ani Pharmaceuticals, INC. | $14.06 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.